KELUN PHARMA(002422) 华福证券·2025-05-23 05:30Investment Rating - The investment rating for the company is "Buy" (maintained) [2][13]. Core Views - The company reported strong performance in 2024, with total revenue reaching 21.81 billion yuan (up 1.7% year-on-year) and net profit attributable to shareholders of 2.94 billion yuan (up 19.5% year-on-year) [4][5]. - The innovative drug segment is accelerating, with significant contributions from various product lines, including raw material intermediates and innovative drugs [5][6]. Financial Performance Summary - In 2024, the company achieved a total revenue of 21.81 billion yuan, with a net profit of 2.94 billion yuan and a non-recurring net profit of 2.90 billion yuan [4]. - For Q1 2025, the company reported a revenue of 4.39 billion yuan (down 29.4% year-on-year) and a net profit of 580 million yuan (down 43.1% year-on-year) [4]. - The company’s major segments, including large-volume infusion, raw material intermediates, and generic drugs, showed stable performance, with notable growth in certain product lines [6]. Segment Performance - The large-volume infusion segment generated sales of 8.91 billion yuan in 2024, despite a decline of 11.85% year-on-year, with a total volume of 4.35 billion bottles/bags [6]. - The non-infusion formulations segment saw a revenue increase of 5.41% year-on-year, reaching 4.17 billion yuan, with significant growth in specific generic products [6]. - The antibiotic intermediates and raw materials segment reported a revenue of 5.86 billion yuan, up 20.9% year-on-year, driven by increased market demand and production efficiency [6]. Innovation and Future Outlook - The successful launch of the innovative drug Jiatailai (Lukangshatuo) is expected to contribute significantly to future revenues, with multiple clinical studies ongoing for various indications [6][13]. - The company anticipates steady performance in its core business and accelerated growth in the innovative drug segment in 2025 [5][13].